Vanda Pharmaceuticals Netherlands Clinical Trials

Company details

Status: Public
HQ: 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
Founded: 2003
Employees: 600
Programs: 60
Drugs: 19
Patents: 96

Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025 Jun 8, 2026

View all news & analysis →

Recent trial activity

8 updates

Latest clinical program signals indexed for Vanda Pharmaceuticals Netherlands.

Trial registry

79 studies

2024-520333-68-00
VP-VHX-896-3201

Phase 3 active small_molecule

Major Depressive Disorder

CTIS ↗
NCT00254202
Iloperidone

Approved active small_molecule

Schizophrenia

CT.gov ↗
NCT00291187
20 mg VEC-162

Phase 3 completed small_molecule

Insomnia

CT.gov ↗
NCT00467441
VSF-173

Phase 2 completed small_molecule

Excessive Somnolence

CT.gov ↗
NCT00490945
VEC-162

Phase 2 completed small_molecule

Circadian Rhythm Sleep Disorders

CT.gov ↗
NCT00548340
VEC-162 20 mg

Phase 3 completed small_molecule

Primary Insomnia

CT.gov ↗
NCT01163032
tasimelteon

Phase 3 active small_molecule

Non 24 Hour Sleep Wake Disorder

CT.gov ↗
NCT01218789
tasimelteon

Phase 3 active small_molecule

Non 24 Hour Sleep Wake Disorder

CT.gov ↗
NCT01271387
tasimelteon

Phase 1 completed small_molecule

Hepatic Impairment

CT.gov ↗
NCT01291511
Iloperidone

Approved active small_molecule

Schizophrenia

CT.gov ↗
NCT01348100
Iloperidone crystalline formulation

Phase 2 completed small_molecule

Schizophrenia

CT.gov ↗
NCT01402076
Tasimelteon

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT01428661
tasimelteon

Phase 3 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT01429116
tasimelteon

Phase 3 active small_molecule

Non 24 Hour Sleep Wake Disorder

CT.gov ↗
NCT01430754
tasimelteon

Phase 3 active small_molecule

Non 24 Hour Sleep Wake Disorder

CT.gov ↗
NCT01477619
Tasimelteon

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT01495169
iloperidone (oral tablet)

Phase 1 completed small_molecule

Safety and Tolerability of Iloperidone

CT.gov ↗
NCT01526746
Tasimelteon

Phase 1 completed small_molecule

Renal Impairment

CT.gov ↗
NCT01540500
Tasimelteon

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT01578057
tasimelteon

Phase 1 completed small_molecule

Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol

CT.gov ↗
NCT01637636
tasimelteon

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT01919944
VLY-686

Phase 1 completed small_molecule

Pruritus

CT.gov ↗
NCT02004041
VLY-686

Phase 2 completed small_molecule

Treatment-resistant Pruritus Associated With Atopic Dermatitis

CT.gov ↗
NCT02130999
tasimelteon 20 mg capsule

Approved completed small_molecule

Non-24-Hour-Sleep-Wake Disorder

CT.gov ↗
NCT02231008
tasimelteon

Phase 3 completed small_molecule

Smith-Magenis Syndrome

CT.gov ↗
NCT02413918
iloperidone

Approved completed small_molecule

Bipolar Disorder

CT.gov ↗
NCT02621385
tradipitant

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT02651714
Tradipitant

Phase 3 completed small_molecule

Atopic Dermatitis

CT.gov ↗
NCT02776215
tasimelteon

Phase 1 completed small_molecule

Circadian Rhythm Sleep Disorders

CT.gov ↗
NCT02970968
VLY-686 (Tradipitant)

Phase 2 completed small_molecule

Gastroparesis

CT.gov ↗
NCT03291041
Tasimelteon

Phase 2 completed small_molecule

Jet Lag Disorder

CT.gov ↗
NCT03373201
Tasimelteon

Phase 3 completed small_molecule

Jet Lag Type Insomnia

CT.gov ↗
NCT03568331
Tradipitant

Phase 3 completed small_molecule

Atopic Dermatitis

CT.gov ↗
NCT03619902
Imsidolimab

Phase 2 completed mab

Generalized Pustular Psoriasis

CT.gov ↗
NCT03633396
Imsidolimab

Phase 2 completed mab

Palmoplantar Pustulosis

CT.gov ↗
NCT03772340
Tradipitant

Phase 3 active small_molecule

Motion Sickness

CT.gov ↗
NCT03838926
Trichostatin A

Phase 1 active small_molecule

Relapsed or Refractory Hematologic Malignancies

CT.gov ↗
NCT04028492
Tradipitant

Phase 3 active small_molecule

Idiopathic Gastroparesis

CT.gov ↗
NCT04127058
Iloperidone

Phase 3 completed small_molecule

Bipolar I Disorder

CT.gov ↗
NCT04140695
Tradipitant

Phase 3 completed small_molecule

Atopic Dermatitis

CT.gov ↗
NCT04326426
Tradipitant

Phase 3 active small_molecule

Coronavirus Infection

CT.gov ↗
NCT04327661
Tradipitant

Phase 3 active small_molecule

Motion Sickness

CT.gov ↗
NCT04622345
VSJ-110

Phase 2 completed small_molecule

Allergic Conjunctivitis

CT.gov ↗
NCT04652882
Tasimelteon

Phase 3 active small_molecule

Sleep Wake Disorders

CT.gov ↗
NCT04697056
Imsidolimab

Phase 2 terminated small_molecule

Ichthyosis

CT.gov ↗
NCT04697069
Imsidolimab

Phase 2 terminated mab

Acneiform Eruptions

CT.gov ↗
NCT04712734
Iloperidone

Approved active small_molecule

Schizophrenia

CT.gov ↗
NCT04800237
VQW-765

Phase 2 completed small_molecule

Performance Anxiety

CT.gov ↗
NCT04819776
Iloperidone

Phase 3 completed small_molecule

Bipolar I Disorder

CT.gov ↗
NCT04849559
Tradipitant

Phase 2 completed small_molecule

Healthy Volunteer

CT.gov ↗
NCT04856917
Imsidolimab

Phase 2 completed small_molecule

Acne Vulgaris

CT.gov ↗
NCT04856930
Imsidolimab

Phase 2 completed mab

Hidradenitis Suppurativa

CT.gov ↗
NCT04969211
VHX-896 and iloperidone

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT05344365
Iloperidone

Phase 2 terminated small_molecule

Parkinson Disease Psychosis

CT.gov ↗
NCT05352893
750 mg Imsidolimab

Phase 3 completed small_molecule

Generalized Pustular Psoriasis

CT.gov ↗
NCT05361707
VP-VEC-162-3601

Phase 3 active small_molecule

Autism Spectrum Disorder

CT.gov ↗
NCT05366855
Double-blind 200 mg imsidolimab

Phase 3 terminated small_molecule

Generalized Pustular Psoriasis

CT.gov ↗
NCT05572281
Tasimelteon Oral Capsule

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT05648591
Iloperidone

Approved active small_molecule

Schizophrenia

CT.gov ↗
NCT05903924
Tradipitant

Phase 3 active small_molecule

Motion Sickness

CT.gov ↗
NCT05922995
Tasimelteon

Phase 1 terminated small_molecule

REM Behavior Disorder

CT.gov ↗
NCT06138613
Tradipitant

Phase 3 active small_molecule

Motion Sickness

CT.gov ↗
NCT06296966
VSJ-110

Phase 2 active small_molecule

Dry Eye

CT.gov ↗
NCT06323655
Tasimelteon

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT06494397
VHX-896 and iloperidone

Phase 1 completed small_molecule

Schizophrenia

CT.gov ↗
NCT06701396
Tasimelteon

Phase 3 active small_molecule

Sleep Wake Disorders

CT.gov ↗
NCT06803290
VHX-896

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT06804603
Tradipitant

Phase 2 completed small_molecule

Obesity

CT.gov ↗
NCT06830044
Milsaperidone

Phase 3 active small_molecule

Major Depressive Disorder (MDD)

CT.gov ↗
NCT06836557
Tradipitant

Phase 3 active small_molecule

Idiopathic Gastroparesis

CT.gov ↗
NCT06953869
Tasimelteon Oral Suspension

Phase 3 active small_molecule

Insomnia Disorder

CT.gov ↗
NCT06961968
Iloperidone

Approved active small_molecule

Schizophrenia

CT.gov ↗
NCT07065773
Trichostatin A

Phase 2 active small_molecule

Onychomycosis of Toenail

CT.gov ↗
NCT07090161
iloperidone

Phase 2 active small_molecule

Hypertension

CT.gov ↗
NCT07179055
VSJ-110

Phase 2 active small_molecule

Dry Eye

CT.gov ↗
NCT07221578
VQW-765

Phase 3 active small_molecule

Social Anxiety Disorder (SAD)

CT.gov ↗
NCT07223632
VCA-894A

Phase 2 active small_molecule

Charcot Marie Tooth Disease (CMT)

CT.gov ↗
NCT07362017
Ponesimod

Phase 3 active small_molecule

Moderate-to-severe Chronic Plaque Psoriasis

CT.gov ↗
NCT07446439
Tradipitant

Phase 3 active small_molecule

Nausea and Vomiting

CT.gov ↗

Recent trial activity

Trial registry

Stay Ahead in Pharma